- ICH GCP
- EU Clinical Trials Registry
Latest Trials
EudraCT Number: 2008-002774-34 | Sponsor Protocol Number: A2581172 | Start Date: | |||||||||||
Sponsor Name: Pfizer Inc,235 East 42nd Street,New York,NY 10017 | |||||||||||||
Full Title: A 8-WEEK, OPEN-LABEL, PHASE 1 STUDY TO EVALUATE PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY AND TOLERABILITY OF ATORVASTATIN IN CHILDREN AND ADOLESCENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | |||||||||||||
Medical condition: HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Not Authorised) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-009597-27 | Sponsor Protocol Number: BAY86-4875/91743 | Start Date: | |||||||||||
Sponsor Name: Bayer Health Care AG (study performed by Bayer Schering Pharma AG) | |||||||||||||
Full Title: An open label, multi-center, phase 3 study with corresponding blinded image reading to determine the efficacy and safety of a single intravenous injection of 0.1 mmol/kg body weight of gadobutrol 1... | |||||||||||||
Medical condition: Patients with histologically confirmed breast cancer referred to MRM prior to surgery after XRM. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FI (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019962-10 | Sponsor Protocol Number: P1-SAF301 | Start Date: | |||||||||||
Sponsor Name: SANFILIPPO Therapeutics SAS | |||||||||||||
Full Title: AN OPEN-LABEL, SINGLE ARM, MONOCENTRIC, PHASE I/II CLINICAL STUDY OF INTRACEREBRAL ADMINISTRATION OF ADENO-ASSOCIATED VIRAL VECTORS SEROTYPE 10 CARRYING THE HUMAN SGSH AND SUMF1 cDNAS FOR THE TREAT... | |||||||||||||
Medical condition: Sanfilippo type A syndrome (also named Mucopolysaccharidosis Type A) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001686-17 | Sponsor Protocol Number: P170925J | Start Date: | |||||||||||
Sponsor Name: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: | |||||||||||||
Medical condition: Patients older than 15 years with hematologic or pulmonary lesions of telomeropathies. | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002526-36 | Sponsor Protocol Number: PVO-1A-204 | Start Date: | |||||||||||
Sponsor Name: Clementia Pharmaceuticals Inc. | |||||||||||||
Full Title: A Phase 2, Open-Label, Efficacy and Safety Study of an RARγ-Specific Agonist (Palovarotene) to Prevent Heterotopic Ossification in Subjects with Fibrodysplasia Ossificans Progressiva (FOP) | |||||||||||||
Medical condition: Fibrodysplasia Ossificans Progressiva (FOP) is a rare, severely disabling disease characterized by painful, recurrent episodes of soft tissue swelling (flare-ups) and abnormal heterotopic ossificat... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005314-34 | Sponsor Protocol Number: SRK-015-003 | Start Date: | |||||||||||
Sponsor Name: Scholar Rock, Inc. | |||||||||||||
Full Title: Phase 3, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Apitegromab (SRK-015) in Patients with Later-Onset Spinal Muscular Atrophy Receiving Background Nusinersen or ... | |||||||||||||
Medical condition: Spinal Muscular Atrophy (SMA) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Ongoing) DE (Ongoing) ES (Ongoing) NL (Ongoing) PL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005522-28 | Sponsor Protocol Number: ION363-CS1 | Start Date: | |||||||||||
Sponsor Name: Ionis Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 1-3 Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION363 in Amyotrophic Lateral Sclerosis Patients with Fused in Sarcoma Mutati... | |||||||||||||
Medical condition: Amyotrophic Lateral Sclerosis with Fused in Sarcoma mutations | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) IT (Ongoing) BE (Ongoing) NL (Ongoing) SE (Ongoing) IE (Ongoing) PL (Ongoing) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003638-10 | Sponsor Protocol Number: 2016_37 | Start Date: | |||||||||||
Sponsor Name: CHRU LILLE | |||||||||||||
Full Title: INTRANASAL CLONIDINE PREDICTION IN PEDIATRIC SURGERY: RANDOMIZED STUDY AGAINST PLACEBO | |||||||||||||
Medical condition: intra-nasal premedication instead of oral, intravenous or no premedication. | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-000793-45 | Sponsor Protocol Number: TMC114-C209 | Start Date: | |||||||||||
Sponsor Name: Tibotec Pharmaceuticals Ltd. | |||||||||||||
Full Title: Open-label safety study of TMC114 in combination with low dose RTV and other ARVs in highly experienced HIV-1 infected patients with limited or no treatment options. | |||||||||||||
Medical condition: HIV-1 infected patient | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002195-90 | Sponsor Protocol Number: SPON1334-14 | Start Date: | ||||||||||||||||
Sponsor Name: Cardiff University | ||||||||||||||||||
Full Title: Adults with acute myeloid leukaemia or high-risk myelodysplastic syndrome (AML19) | ||||||||||||||||||
Medical condition: Acute myeloid leukaemia High Risk Myelodysplastic Syndrome (trial arm for this patient group is now closed awaiting final analysis) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DK (Completed) | ||||||||||||||||||
Trial results: (No results available) |